Skip to content
Search

Latest Stories

Avril Chester to join RPS as Chief Technology Officer from June

The Royal Pharmaceutical Society (RPS) has appointed Avril Chester as its new Chief Technology Officer.

Avril joins the RPS in June and will be accountable for the development and implementation of the RPS technology and digital strategy. Last year RPS launched a new platform for the Pharmaceutical Journal and plans to develop more digital products and services for our members and customers.


In her new role, Avril will have responsibility for executive leadership of all the technology functions, including technical architecture, software development, operations and product delivery. Avril will report directly to the Chief Executive, Paul Bennett, and joins the Society’s Executive team in June.

Avril is currently Chief Technology Officer at the Royal Institute of British Architects. Alongside that, she is an award-winning technology entrepreneur, author, podcast host and founder of a cancer charity. She was also finalist for CTO of the Year at the Women in IT awards 2022.

Paul Bennett, CEO said: "I am delighted that Avril will be joining our Executive team and leading our technology function and our digital strategy. We have a strong technology team within RPS and Avril's appointment strengthens that further as she brings great energy, drive, experience and enthusiasm with her and my colleagues and I very much look forward to working closely with her as we further develop our technological capability"

Commenting on her appointment Avril said: “It is a real honour to support our incredible pharmacists and pharmaceutical scientists and I am over the moon to have this opportunity to join the Royal Pharmaceutical Society. Technology has and continues to impact our lives, especially in healthcare and medicine. The RPS already embraces the technology evolution and I look forward to continuing this great work and push even more digital boundaries to champion and support the profession”.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less